BACKGROUND: The goals of asthma treatment include preventing recurrent exacerbations. Yet there is no consensus about the terminology for describing or defining "exacerbation" or about how to characterize an episode's severity. OBJECTIVE: National Institutes of Health institutes and other federal agencies convened an expert group to propose how asthma exacerbation should be assessed as a standardized asthma outcome in future asthma clinical research studies. METHODS: We used comprehensive literature reviews and expert opinion to compile a list of asthma exacerbation outcomes and classified them as either core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at a National Institutes of Health-organized workshop in March 2010 and finalized in September 2011. RESULTS: No dominant definition of "exacerbation" was found. The most widely used definitions included 3 components, all related to treatment, rather than symptoms: (1) systemic use of corticosteroids, (2) asthma-specific emergency department visits or hospitalizations, and (3) use of short-acting β-agonists as quick-relief (sometimes referred to as "rescue" or "reliever") medications. CONCLUSIONS: The working group participants propose that the definition of "asthma exacerbation" be "a worsening of asthma requiring the use of systemic corticosteroids to prevent a serious outcome." As core outcomes, they propose inclusion and separate reporting of several essential variables of an exacerbation. Furthermore, they propose the development of a standardized, component-based definition of "exacerbation" with clear thresholds of severity for each component. Published by Mosby, Inc.
BACKGROUND: The goals of asthma treatment include preventing recurrent exacerbations. Yet there is no consensus about the terminology for describing or defining "exacerbation" or about how to characterize an episode's severity. OBJECTIVE: National Institutes of Health institutes and other federal agencies convened an expert group to propose how asthma exacerbation should be assessed as a standardized asthma outcome in future asthma clinical research studies. METHODS: We used comprehensive literature reviews and expert opinion to compile a list of asthma exacerbation outcomes and classified them as either core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at a National Institutes of Health-organized workshop in March 2010 and finalized in September 2011. RESULTS: No dominant definition of "exacerbation" was found. The most widely used definitions included 3 components, all related to treatment, rather than symptoms: (1) systemic use of corticosteroids, (2) asthma-specific emergency department visits or hospitalizations, and (3) use of short-acting β-agonists as quick-relief (sometimes referred to as "rescue" or "reliever") medications. CONCLUSIONS: The working group participants propose that the definition of "asthma exacerbation" be "a worsening of asthma requiring the use of systemic corticosteroids to prevent a serious outcome." As core outcomes, they propose inclusion and separate reporting of several essential variables of an exacerbation. Furthermore, they propose the development of a standardized, component-based definition of "exacerbation" with clear thresholds of severity for each component. Published by Mosby, Inc.
Authors: Jerry A Krishnan; Kristin A Riekert; Jonathan V McCoy; Dana Y Stewart; Spencer Schmidt; Arjun Chanmugam; Peter Hill; Cynthia S Rand Journal: Am J Respir Crit Care Med Date: 2004-09-16 Impact factor: 21.405
Authors: Aaron Deykin; Michael E Wechsler; Homer A Boushey; Vernon M Chinchilli; Susan J Kunselman; Timothy J Craig; Emily DiMango; John V Fahy; Monica Kraft; Frank Leone; Stephen C Lazarus; Robert F Lemanske; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Elliot Israel Journal: Am J Respir Crit Care Med Date: 2006-09-14 Impact factor: 21.405
Authors: Eric D Bateman; Jose Luis Izquierdo; Ulf Harnest; Peter Hofbauer; Pal Magyar; Christine Schmid-Wirlitsch; Stefan Leichtl; Dirk Bredenbröker Journal: Ann Allergy Asthma Immunol Date: 2006-05 Impact factor: 6.347
Authors: Douglas M Fleming; Pietro Crovari; Ulrich Wahn; Timo Klemola; Yechiel Schlesinger; Alexangros Langussis; Knut Øymar; Maria Luz Garcia; Alain Krygier; Herculano Costa; Ulrich Heininger; Jean-Louis Pregaldien; Sheau-Mei Cheng; Jonathan Skinner; Ahmad Razmpour; Melanie Saville; William C Gruber; Bruce Forrest Journal: Pediatr Infect Dis J Date: 2006-10 Impact factor: 2.129
Authors: Jacqueline A Pongracic; Cynthia M Visness; Rebecca S Gruchalla; Richard Evans; Herman E Mitchell Journal: Ann Allergy Asthma Immunol Date: 2008-07 Impact factor: 6.347
Authors: Martha P Montgomery; Elizabeth D Allen; Olivia Thomas; Byron F Robinson; Donnie Clark; Ann Connelly; Joshua A Mott; Elizabeth Conrey Journal: J Asthma Date: 2018-06-14 Impact factor: 2.515
Authors: E Sherwood Brown; Nasreen Sayed; Erin Van Enkevort; Alexandra Kulikova; Alyson Nakamura; David A Khan; Elena I Ivleva; Prabha Sunderajan; Bruce G Bender; Traci Holmes Journal: J Allergy Clin Immunol Pract Date: 2018-03-01
Authors: Matthew A Rank; Ryan Johnson; Megan Branda; Jeph Herrin; Holly van Houten; Michael R Gionfriddo; Nilay D Shah Journal: Chest Date: 2015-09 Impact factor: 9.410
Authors: Christian Rosas-Salazar; Sima K Ramratnam; John M Brehm; Yueh-Ying Han; Edna Acosta-Pérez; María Alvarez; Angel Colón-Semidey; Glorisa Canino; Andrea J Apter; Juan C Celedón Journal: Chest Date: 2013-07 Impact factor: 9.410
Authors: Jennifer A Rumpel; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Mao Yang; Albert M Levin; James J Yang; Rajesh Kumar; Esteban González Burchard; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-10-12 Impact factor: 10.793
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793